These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [New medications; bevacizumab]. Cohen AF; van Bronswijk H Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430 [TBL] [Abstract][Full Text] [Related]
3. Bevacizumab: one treatment for all the seasons? Gelibter AJ; Di Segni S; Zeuli M; Cognetti F J Clin Oncol; 2008 Jan; 26(3):511; author reply 511-2. PubMed ID: 18202430 [No Abstract] [Full Text] [Related]
4. Bevacizumab beyond progression: does this make sense? Ellis LM; Haller DG J Clin Oncol; 2008 Nov; 26(33):5313-5. PubMed ID: 18854567 [No Abstract] [Full Text] [Related]
5. Introduction. Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer. Díaz-Rubio E; Schmoll HJ Oncology; 2005; 69 Suppl 3():1-3. PubMed ID: 16301829 [No Abstract] [Full Text] [Related]
6. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Ferrara N; Hillan KJ; Gerber HP; Novotny W Nat Rev Drug Discov; 2004 May; 3(5):391-400. PubMed ID: 15136787 [No Abstract] [Full Text] [Related]
8. [Role of angiogenesis inhibitors in the treatment of colorectal cancer]. Bodoky G Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870 [TBL] [Abstract][Full Text] [Related]
9. The role of new agents in the treatment of colorectal cancer. Ruiz de Erenchun F Oncology; 2005; 68(2-3):162; author reply 162. PubMed ID: 16097096 [No Abstract] [Full Text] [Related]
10. Body fatness and bevacizumab-based therapy in metastatic colorectal cancer. Renehan AG Gut; 2010 Mar; 59(3):289-90. PubMed ID: 20207633 [No Abstract] [Full Text] [Related]
12. Regression of a subfoveal choroidal metastasis of colorectal carcinoma after intravitreous bevacizumab treatment. Kuo IC; Haller JA; Maffrand R; Sambuelli RH; Reviglio VE Arch Ophthalmol; 2008 Sep; 126(9):1311-3. PubMed ID: 18779499 [No Abstract] [Full Text] [Related]
13. Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer. Tyagi P Clin Colorectal Cancer; 2006 Sep; 6(3):189-91. PubMed ID: 17026787 [No Abstract] [Full Text] [Related]
14. [Indication Avastin in ophthalmology]. Studnicka J Cesk Slov Oftalmol; 2010 Nov; 66(5):229-33. PubMed ID: 21394981 [TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses? Abbadessa G; Vogiatzi P; Rimassa L; Claudio PP Drug News Perspect; 2007 Jun; 20(5):307-13. PubMed ID: 17878958 [TBL] [Abstract][Full Text] [Related]
17. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Collins TS; Hurwitz HI Semin Oncol; 2005 Feb; 32(1):61-8. PubMed ID: 15726507 [TBL] [Abstract][Full Text] [Related]
18. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Los M; Roodhart JM; Voest EE Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687 [TBL] [Abstract][Full Text] [Related]
19. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Thornton AD; Ravn P; Winslet M; Chester K Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389 [TBL] [Abstract][Full Text] [Related]